NASDAQ:BFRI Biofrontera (BFRI) Stock Price, News & Analysis $0.75 -0.01 (-1.31%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Biofrontera Stock (NASDAQ:BFRI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biofrontera alerts:Sign Up Key Stats Today's Range$0.73▼$0.7650-Day Range$0.71▼$1.4052-Week Range$0.61▼$8.20Volume81,234 shsAverage Volume384,071 shsMarket Capitalization$3.82 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company OverviewBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Read More… Crypto’s next big bull run? (Ad)Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …And one special coin could do even better. Biofrontera Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreBFRI MarketRank™: Biofrontera scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiofrontera has only been the subject of 1 research reports in the past 90 days.Read more about Biofrontera's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biofrontera are expected to grow in the coming year, from ($3.11) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biofrontera is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biofrontera is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiofrontera has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Biofrontera's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.13% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently increased by 49.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiofrontera does not currently pay a dividend.Dividend GrowthBiofrontera does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.13% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently increased by 49.26%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News SentimentN/A News SentimentBiofrontera has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biofrontera this week, compared to 0 articles on an average week.Search Interest3 people have searched for BFRI on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biofrontera insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.21% of the stock of Biofrontera is held by insiders.Percentage Held by InstitutionsOnly 10.08% of the stock of Biofrontera is held by institutions.Read more about Biofrontera's insider trading history. Receive BFRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address BFRI Stock News HeadlinesBiofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)October 14, 2024 | globenewswire.comBiofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...October 9, 2024 | finance.yahoo.comDon’t Buy Another Stock Until Reading This…Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my upcoming FREE intro to investing online event, my team will be revealing the strategies I've developed over the past 37 years on Wall Street…October 18, 2024 | Unstoppable Prosperity (Ad)Biofrontera: FDA Approves SNDA To Increase Maximally Approved Dosage Of Ameluz - Quick FactsOctober 8, 2024 | markets.businessinsider.comFDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One TreatmentOctober 8, 2024 | markets.businessinsider.comFDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One TreatmentOctober 7, 2024 | globenewswire.comBiofrontera Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagAugust 18, 2024 | finance.yahoo.comBiofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business UpdateAugust 14, 2024 | globenewswire.comSee More Headlines BFRI Stock Analysis - Frequently Asked Questions How have BFRI shares performed this year? Biofrontera's stock was trading at $2.77 at the start of the year. Since then, BFRI shares have decreased by 72.9% and is now trading at $0.7510. View the best growth stocks for 2024 here. How were Biofrontera's earnings last quarter? Biofrontera Inc. (NASDAQ:BFRI) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($1.19) by $0.07. The business had revenue of $7.84 million for the quarter, compared to the consensus estimate of $9.02 million. Biofrontera had a negative net margin of 38.34% and a negative trailing twelve-month return on equity of 837.97%. When did Biofrontera's stock split? Biofrontera's stock reverse split on Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Biofrontera IPO? Biofrontera (BFRI) raised $19 million in an initial public offering on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO. How do I buy shares of Biofrontera? Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Biofrontera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NVIDIA (NVDA), NIO (NIO) and Meta Platforms (META). Company Calendar Last Earnings8/14/2024Today10/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BFRI CUSIPN/A CIK1858685 Webwww.biofrontera-us.com Phone781-245-1325FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+832.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($13.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,130,000.00 Net Margins-38.34% Pretax Margin-38.29% Return on Equity-837.97% Return on Assets-87.73% Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.46 Sales & Book Value Annual Sales$35.24 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$3.16 per share Price / Book0.24Miscellaneous Outstanding Shares5,089,000Free Float5,531,000Market Cap$3.82 million OptionableNo Data Beta0.50 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BFRI) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersDon’t Buy Another Stock Until Reading This…Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my up...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.